303 related articles for article (PubMed ID: 12153599)
21. Safety of estrogen/androgen regimens.
Simon JA
J Reprod Med; 2001 Mar; 46(3 Suppl):281-90. PubMed ID: 11304876
[TBL] [Abstract][Full Text] [Related]
22. Effects of hormone replacement therapies on fibrinogen and plasma viscosity in postmenopausal women.
Fröhlich M; Schunkert H; Hense HW; Tropitzsch A; Hendricks P; Döring A; Riegger GA; Koenig W
Br J Haematol; 1998 Mar; 100(3):577-81. PubMed ID: 9504644
[TBL] [Abstract][Full Text] [Related]
23. Vasodilator effects of estrogen are not diminished by androgen in postmenopausal women.
Sarrel PM; Wiita B
Fertil Steril; 1997 Dec; 68(6):1125-7. PubMed ID: 9418709
[TBL] [Abstract][Full Text] [Related]
24. The contribution of SHBG to the variation in HOMA-IR is not dependent on endogenous oestrogen or androgen levels in postmenopausal women.
Davis SR; Robinson PJ; Moufarege A; Bell RJ
Clin Endocrinol (Oxf); 2012 Oct; 77(4):541-7. PubMed ID: 22106826
[TBL] [Abstract][Full Text] [Related]
25. Endogenous estrogen and androgen levels are not independent predictors of lipid levels in postmenopausal women.
Worsley R; Robinson PJ; Bell RJ; Moufarege A; Davis SR
Menopause; 2013 Jun; 20(6):640-5. PubMed ID: 23531683
[TBL] [Abstract][Full Text] [Related]
26. Effect of conjugated equine estrogen in combination with two different progestogens on the risk factors of coronary heart disease in postmenopausal Chinese women in Taiwan: a randomized one-year study.
Chang TC; Lien YR; Chen M; Cheng SP; Chen RJ; Chow SN
Acta Obstet Gynecol Scand; 2004 Jul; 83(7):661-6. PubMed ID: 15225192
[TBL] [Abstract][Full Text] [Related]
27. Beneficial effects on serum lipoproteins by 17 beta-oestradiol-dydrogesterone therapy in postmenopausal women; a prospective study.
van der Mooren MJ; Demacker PN; Thomas CM; Rolland R
Eur J Obstet Gynecol Reprod Biol; 1992 Nov; 47(2):153-60. PubMed ID: 1459329
[TBL] [Abstract][Full Text] [Related]
28. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles.
Barrett-Connor E; Young R; Notelovitz M; Sullivan J; Wiita B; Yang HM; Nolan J
J Reprod Med; 1999 Dec; 44(12):1012-20. PubMed ID: 10649811
[TBL] [Abstract][Full Text] [Related]
29. Endogenous oestradiol as a positive correlate of plasma fibrinogen among older postmenopausal women: a population-based study (the Three-City cohort study).
Canonico M; Brailly-Tabard S; Gaussem P; Setiao J; Rouaud O; Ryan J; Carcaillon L; Guiochon-Mantel A; Scarabin PY
Clin Endocrinol (Oxf); 2012 Dec; 77(6):905-10. PubMed ID: 22642405
[TBL] [Abstract][Full Text] [Related]
30. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
Stephenson K; Neuenschwander PF; Kurdowska AK
Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249
[TBL] [Abstract][Full Text] [Related]
31. Response of plasma low density lipoprotein subfractions to oestrogen replacement therapy following surgical menopause.
Griffin B; Farish E; Walsh D; Barnes J; Caslake M; Shepherd J; Hart D
Clin Endocrinol (Oxf); 1993 Oct; 39(4):463-8. PubMed ID: 8287573
[TBL] [Abstract][Full Text] [Related]
32. A comparison of esterified estrogens with and without methyltestosterone: effects on endometrial histology and serum lipoproteins in postmenopausal women.
Hickok LR; Toomey C; Speroff L
Obstet Gynecol; 1993 Dec; 82(6):919-24. PubMed ID: 8233265
[TBL] [Abstract][Full Text] [Related]
33. Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women.
Nugent AG; Leung KC; Sullivan D; Reutens AT; Ho KK
Clin Endocrinol (Oxf); 2003 Dec; 59(6):690-8. PubMed ID: 14974909
[TBL] [Abstract][Full Text] [Related]
34. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
[TBL] [Abstract][Full Text] [Related]
35. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause.
Stomati M; Monteleone P; Casarosa E; Quirici B; Puccetti S; Bernardi F; Genazzani AD; Rovati L; Luisi M; Genazzani AR
Gynecol Endocrinol; 2000 Oct; 14(5):342-63. PubMed ID: 11109974
[TBL] [Abstract][Full Text] [Related]
36. Phasic serum lipid excursions occur during cyclical oral conjugated oestrogens but not during transdermal oestradiol sequentially combined with oral medroxyprogesterone acetate.
Lemay A; Dodin S; Cédrin I; T-Lemay L
Clin Endocrinol (Oxf); 1995 Apr; 42(4):341-51. PubMed ID: 7750187
[TBL] [Abstract][Full Text] [Related]
37. Low-dose progesterone therapy in oestrogenised postmenopausal women: effects on plasma lipids, lipoproteins and liver function parameters.
Bolaji II; Grimes H; Mortimer G; Tallon DF; Fottrell PF; O'Dwyer EM
Eur J Obstet Gynecol Reprod Biol; 1993 Jan; 48(1):61-8. PubMed ID: 8449263
[TBL] [Abstract][Full Text] [Related]
38. Responses of HDL subclasses, Lp(A-I) and Lp(A-I:A-II) levels and lipolytic enzyme activities to continuous oral estrogen-progestin and transdermal estrogen with cyclic progestin regimens in postmenopausal women.
Tilly-Kiesi M; Kahri J; Pyörälä T; Puolakka J; Luotola H; Lappi M; Lahdenperä S; Taskinen MR
Atherosclerosis; 1997 Mar; 129(2):249-59. PubMed ID: 9105568
[TBL] [Abstract][Full Text] [Related]
39. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women.
Darling GM; Johns JA; McCloud PI; Davis SR
N Engl J Med; 1997 Aug; 337(9):595-601. PubMed ID: 9271481
[TBL] [Abstract][Full Text] [Related]
40. Oestrogen effects on calcitriol levels in post-menopausal women: a comparison of oral versus transdermal administration.
Dick IM; Prince RL; Kelly JJ; Ho KK
Clin Endocrinol (Oxf); 1995 Aug; 43(2):219-24. PubMed ID: 7554318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
